Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Stoke Therapeutics Inc (NASDAQ: STOK) closed the day trading at $23.88 up 5.38% from the previous closing price of $22.66. In other words, the price has increased by $5.38 from its previous closing price. On the day, 0.99 million shares were traded. STOK stock price reached its highest trading level at $24.0 during the session, while it also had its lowest trading level at $22.4.
Ratios:
For a better understanding of STOK, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.40. For the most recent quarter (mrq), Quick Ratio is recorded 6.98 and its Current Ratio is at 6.98. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on July 18, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 02 ’25 when Ticho Barry sold 5,501 shares for $19.87 per share. The transaction valued at 109,325 led to the insider holds 18,469 shares of the business.
Kaye Edward M. MD sold 45,996 shares of STOK for $925,858 on Sep 03 ’25. The Director now owns 91,585 shares after completing the transaction at $20.13 per share. On Sep 02 ’25, another insider, Kaye Edward M. MD, who serves as the Director of the company, sold 14,860 shares for $20.14 each. As a result, the insider received 299,260 and left with 137,581 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STOK now has a Market Capitalization of 1308561920 and an Enterprise Value of 1064405312. As of this moment, Stoke’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.26. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.55 while its Price-to-Book (P/B) ratio in mrq is 3.90. Its current Enterprise Value per Revenue stands at 5.325 whereas that against EBITDA is 25.181.
Stock Price History:
The Beta on a monthly basis for STOK is 1.22, which has changed by 0.650311 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, STOK has reached a high of $22.79, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 52.66%, while the 200-Day Moving Average is calculated to be 110.94%.
Shares Statistics:
Over the past 3-months, STOK traded about 798.92K shares per day on average, while over the past 10 days, STOK traded about 913240 shares per day. A total of 54.72M shares are outstanding, with a floating share count of 46.00M. Insiders hold about 16.06% of the company’s shares, while institutions hold 112.44% stake in the company. Shares short for STOK as of 1756425600 were 10737735 with a Short Ratio of 13.44, compared to 1753920000 on 11430622. Therefore, it implies a Short% of Shares Outstanding of 10737735 and a Short% of Float of 23.69.
Earnings Estimates
A comprehensive evaluation of Stoke Therapeutics Inc (STOK) is underway, with the input of 9.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.54 and low estimates of -$0.81.
Analysts are recommending an EPS of between $0.48 and -$0.1 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is -$2.92, with 9.0 analysts recommending between -$2.3 and -$3.65.
Revenue Estimates
10 analysts predict $6.06M in revenue for the current quarter. It ranges from a high estimate of $12M to a low estimate of $3M. As of the current estimate, Stoke Therapeutics Inc’s year-ago sales were $4.89MFor the next quarter, 10 analysts are estimating revenue of $5.47M. There is a high estimate of $11M for the next quarter, whereas the lowest estimate is $3M.
A total of 11 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $205.8M, while the lowest revenue estimate was $178.39M, resulting in an average revenue estimate of $185.57M. In the same quarter a year ago, actual revenue was $36.55M
